Comparison of solifenacin versus mirabegron for the treatment of double j stent related lower urinary tract symptoms
DOI:
https://doi.org/10.61581/MJSP.VOL06/01/07Keywords:
Overactive bladder, Mirabegron, Urgency, SolifenacinAbstract
Objective: Overactive bladder is mostly treated with a combination of behavioural interventions
and commonly prescribed anti-muscarinic medication therapy, including solifenacin, which has
considerable side effects and lowers the quality of life. Mirabegron relaxes the detrusor muscle and
is a recently approved drug for the treatment of OAB. This study examined the effectiveness and
safety of two medications, solifenacin and mirabegron.
Methods: This study was a comparative
cross-sectional study conducted at Sami Medical Center, Abbottabad for a period of 6 months from
August 2022 to January 2023. Female patients of aged ?18 years with symptoms of OAB were
enrolled.
Results: Current study showed that the average age of patients was 37.47±12.48 years in
Group S and 39.93±7.93 in Group M. The population consists of 60 (100%) females. After 4 weeks
of follow up dizziness, dry mouth, constipation hypertension and blurred vision were found
insignificant between both groups with p-values of 0.312, 0.161, 0.076, 0.076, and 0.313 respectively.
OABSS score improved significantly and after therapy 4.20±1.32 in Group S and 3.43±1.13 in Group
M. There was no significant difference in frequency of treatment withdrawal p-value 0.150.
Conclusion:When it comes to relieving symptoms of OAB, both solifenacin and mirabegron are effective. The
OABSS improved with both drugs; however, mirabegron was associated with fewer treatment-related
adverse events. We advocate using mirabegron as the first-line treatment. Solifenacin can be utilized if
patients are no longer getting the desired effects from Mirabegron.
Downloads
References
1. Damiano R, Autorino R, De Sio M, Giacobbe A, Palumbo IM, D’Armiento M. Effect of tamsulosin in the treatment of urinary symptoms induced by ureteral stents. Eur Urol. 2001;40(4):458–63.
2. Norris RD, Sur RL, Springhart WP, Marguet CG, Mathias BJ, Pietrow PK, et al. A prospective randomized trial comparing the use of extended-release oxybutynin vs. phenazopyridine for stent-related symptoms. J Endourol. 2008;22(3):473–8.
3. Chapple CR, Kaplan SA, Mitcheson D, Klecka J, Cummings J, Silva F, et al. Randomized double-blind, active-controlled phase 3 study to assess 12-month safety of mirabegron in overactive bladder. Eur Urol. 2013;63(2):296–305.
4. Barghi MR, Nasseh H, Latifnejad Roudsari R, Moghaddam KG. Comparison of mirabegron and solifenacin for stent-related lower urinary tract symptoms: A randomized clinical trial. Urol J. 2021;18(2):145–51.
5. Kumar R, Patil M, Hemal AK. β3-Adrenergic receptor agonist for relieving ureteral stent symptoms: A prospective comparison with anticholinergics. Int Braz J Urol. 2020;46(4):606–14.
6. Michel MC, Oelke M. Antimuscarinic drugs for overactive bladder treatment: Efficacy, tolerability, and quality-of-life outcomes. Urology. 2005;66(5 Suppl):38–46.
7. Yamaguchi O, Marui E, Kakizaki H, Homma Y, Igawa Y, Takeda M, et al. Phase III, randomized, double-blind, placebo-controlled study of mirabegron in Japanese patients with overactive bladder. Low Urin Tract Symptoms. 2014;6(2):65–76.
8. Palinggi E, Palinrungi MA, Palinrungi AM, Seweng A, Kholis K, Syahrir S, Faruk M. Effectiveness of using Solifenacin compared to Mirabegron after double-J stent installation for treatment of lower urinary tract symptoms (LUTS). Journal of Medical & Allied Sciences. 2020;10(2):115-20.
9. Tang QL, Zhou S, Liu YQ, Wu J, Tao RZ. Efficacy and safety of combination of mirabegron and solifenacin in patients with double-J stent related overactive bladder: a prospective study. Scientific Reports. 2022 Nov 7;12(1):18844.
10. Elmarakbi AA, Elsayed OM, Mohamed TR, Lotfy AM. Relief of double-J stent-related symptoms: a comparison between mirabegron, tamsulosin and solifenacin. Beni-Suef University Journal of Basic and Applied Sciences. 2024 Jun 24;13(1):62.
11. Galal E, Abdelhamid MH, El-Bab TF, Abdelhamid A. The role of mirabegron in relieving double-J stent-related discomfort: a randomized controlled clinical trial. Central European journal of urology. 2021 Feb 12;74(1):76.
12. Xiang N, Hu Y, Peng W, Luo M, Yang Y, Zhang Q. Comparing efficacy and safety of mirabegron, tamsulosin, and solifenacin in ureteral stent–related symptoms: outcomes from a network meta-analysis. Transl Androl Urol. 2024;13(5):699–707.
13. Abdelaziz AS, Salama NM, Ghoneem AM. Mirabegron vs. solifenacin in control of endoscopically inserted ureteral stent-related symptoms. World J Urol. 2022 Aug;40(8):2113-2119.
14. Chapple C. The efficacy and safety of mirabegron compared with solifenacin in overactive bladder patients dissatisfied with previous antimuscarinic treatment: a Phase IIIb noninferiority trial. BJU Int. 2015;115(5):622–631.
15. Kim SC, Park M, Chae C. Efficacy and tolerability of mirabegron compared with solifenacin for children with idiopathic overactive bladder: a preliminary study. Investig Clin Urol. 2021;62(3):317–323.
16. Schiavi MC, Faiano P, D'Oria O, Zullo MA, Muzii L, Benedetti Panici P. Efficacy and tolerability of treatment with mirabegron compared with solifenacin in the management of overactive bladder syndrome: A retrospective analysis. J Obstet Gynaecol Res. 2018;44(3):524-531.
17. Chandna A, Kumar S, Parmar KM, Sharma AP, Devana SK, Mete UK, Singh SK. Comparison of stent related symptoms in patients taking mirabegron, solifenacin, or tamsulosin: A double blinded randomized clinical trial. Urologia. 2022 Nov;89(4):589-596.
18. Lu Y, Li Q, Zou Q, Cui Y. The efficacy and safety of mirabegron in treating ureteral stent-related symptoms: a systematic review and meta-analysis. Low Urin Tract Symptoms. 2021;14(1):27–34.
19. Palinggi E, Palinrungi MA, Palinrungi AM, Seweng A, Kholis K, Syahrir S, Faruk M. Effectiveness of using Solifenacin compared to Mirabegron after double-J stent installation for treatment of lower urinary tract symptoms (LUTS). Journal of Medical & Allied Sciences. 2020;10(2):115-20.
20. Liao P, Zeng X, Shen H, Luo D. Efficacy and safety of combinations of mirabegron and solifenacin in patients with overactive bladder: a systematic review and meta-analysis. Int J Clin Exp Med. 2019;12(2):1355–1365.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Ali Hussain
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution (CC-BY) 4.0 License that allows others to share the work with an acknowledgment of the work’s authorship and initial publication in this journal.
